Summary Long-term outcome was reviewed in 266 consecutive patients with metastatic non-seminomatous germ cell tumours treated at a single institution. The overall 3 year survival was 77%, and 3 year progressionfree survival was 71 %. Multivariate analysis identified the following clinical features as independent prognostic factors: the presence of liver, bone or brain metastasis, serum human chorionic gonadotropin k 10000 U 1 -1 and/or alpha-fetoprotein > 1000 ng ml-1, a mediastinal mass> 5 cm and the presence of 20 or more lung metastases. Age was not of prognostic significance. Patients without any of the above poor-risk factors had a 3-year survival of 91 % regardless of etoposide-or vinblastine-containing chemotherapy compared with 61 % for the remaining patients. However, etoposide-containing protocols led to significantly improved survival in patients with at least one poor risk factor. After 612 patient-years of observation no case of secondary leukaemia was observed among 119 surviving patients who had received etoposide as part of their treatment. With a median follow-up of 93 months, five patients developed a second germ cell tumour, two patients nongerm cell malignancies. Fourteen patients relapsed after a disease-free interval of more than 2 years, and nine patients died more than 5 years after commencement of treatment underscoring the need to report long-term results. There is some evidence that cumulative experience translates into improved survival and cure rates for patients with poor-risk metastatic disease.
Testicular cancer is the most common neoplasm in males aged under 40. Cisplatin-based combination chemotherapy has dramatically improved the clinical outcome of patients with metastatic non-seminomatous germ cell tumours (NSGCTs) (Einhorn and Donohue, 1977; Horwich, 1989) . However, approximately 20% of patients with metastatic NSGCT still die of their disease. Recently, the second Medical Research Council (MRC) study including data from 795 patients with metastatic NSGCT from 13 centres defined a simple prognostic classification using four clinical features as prognostic variables. Whereas good-risk patients had a 3 year survival of 93%, patients with at least one of the adverse features had a 3 year survival rate of 67% (Mead et al., 1992) .
The present paper analyses our single institution experience in the management of metastatic NSGCT during the cisplatin era. The above-mentioned prognostic model is tested on our data set, and the prognostic relevance of age is assessed. Particular emphasis is put on whether the substitution of etoposide for vinblastine translates into an improved survival. Moreover, we describe the incidence of late relapses and second malignancies.
Patients and methods
Patient characteristics A total of 266 consecutive patients with metastatic NSGCT underwent primary cisplatin-based chemotherapy at Klinikum Grosshadern between May 1979 and June 1995. Patients with stage IIA/B were predominantly treated surgically, the majority of whom received adjuvant chemotherapy. The latter patient group was not included in this study; results have been reported elsewhere (Gerl et al., 1994a) .
The median age at diagnosis was 27 years (range, 16-72 years). Histology was established according to the British Testicular Tumour Panel criteria (Pugh, 1976) . No primary histology was available in four cases, but a considerable elevation of serum human chorionic gonadotropin (HCG) and/or alpha-fetoprotein (AFP) indicated the presence of NSGCT. Two patients had pure seminomas in their testicular primaries, but high levels of HCG (both cases) and AFP (one case) disclosed the presence of NSGCT. Prechemotherapy staging consisted of physical examination, laboratory testing including serum tumour marker determination, chest radiograph and abdominal and thoracic computerised tomography (CT) scans. Further examinations were performed as indicated by clinical symptoms. The characteristics of the 266 patients pertaining to the status immediately before initiation of chemotherapy are summarised in Table L   Treatment Up to 1983 all patients received chemotherapy according to the PVB protocol consisting of cisplatin 20 mg m-2 on days 1-5, vinblastine 0.15-0.20 mg kg-' on days 1 and 2, and bleomycin 30 mg on days 2, 9 and 16 (Einhorn and Donohue, 1977) . Since the end of 1983 patients with a large tumour burden have been predominantly treated according to the ECBC regimen consisting of etoposide 120 mg m-2 on days 1-4, cisplatin 30 mg m-2 on days 1-4, bleomycin 15 mg on day 1 (bolus) and 12 mg m-2 on days 1-4 (24 h infusion), and cyclophosphamide 300 mg m-2 on days 1-4 (Gerl et al., 1993) . In 1987 we began to treat patients with low-volume metastatic disease according to the PEB protocol substituting etoposide 100 mg m-2 on days 1 -5 for vinblastine (Williams et al., 1987) . Few patients received cisplatin-ifosfamide-based chemotherapy with either vinblastine (VIP) or etoposide (EIP) or other cisplatin combinations (Table II) . Patients who achieved normalisation of serum tumour markers but had radiographic abnormalities were alloted to adjunctive post-chemotherapy surgery. Some patients underwent multiple surgical interventions (Gerl et al., 1994b (Gerl et al., 1995a) . Few patients with chemorefractory but localised disease that was deemed resectable were also alloted to post-chemotherapy surgery (Gerl et al., 1995b) . The type and number of surgical interventions are summarised in Table II. Evaluation of response Complete response 1 (CR1) was defined as total disappearance of clinical, radiological and biochemical signs of disease for at least 4 weeks. Patients who had a complete resection of residual masses containing only necrosis/fibrosis or mature teratoma also qualified for CR1. CR2 was defined as disappearance of disease after complete resection of viable Statistical analysis Survival was measured from the date of commencement of chemotherapy-Survival curves were constructed using the Kaplan-Meier method (Kaplan and Meier, 1958) , and comparative survival of subgroups was determined by the log-rank test (Mantel and Haenszel, 1959) . All variables achieving a log-rank P-value of less than 0.05 were included in a multivariate analysis to identify independent prognostic factors. Cox's proportional hazards regression model (Tibshirani, 1982) was used with the statistical package BMDP (Dixon, 1990 ) and a forward stepwise selection procedure. All P-value statistics quoted are on 1 d.f., unless otherwise stated.
Results

Response and survival
A total of 205 patients (77%) achieved a CR, 11 patients (4%) a Rm- (Table III) . Primary treatment failure occurred in 37 patients (14%). Response could not be assessed in six patients, who died within 2 months from start of chemotherapy. Seven patients (2.6%) died owing to chemotherapy-related toxicity: three as a result of neutropenic septicaemia, two owing to bleomycin-induced pulmonary toxicity, and two due to cerebral infarction.
Median follow-up time of surviving patients was 93 months (range, 6-193 Two patients developed non-germ cell malignancies on follow-up. One of these patients, who had been treated according to the PVB schedule, died from non-Hodgkin's lymphoma at 38 months; an association between germ cell tumour chemotherapy and the second malignancy seems uncertain. The second patient developed a glioblastoma 115 months after whole brain irradiation for a cerebral relapse and died 11 months later; a relation between radiotherapy and the second cancer seems probable. A total of 119 surviving patients had received etoposide as part of their primary or salvage treatment, in 31 of whom (26%) the cumulative dose exceeded 2000 mg m-2. After a total of 612 patient-years of observation none of the 119 patients developed a secondary leukaemia.
One patient in CR died due to a car accident at 164 months; this death was considered as a censoring event. In the final evaluation, 182 patients (68%) were alive with NED status, eight were alive with negative markers and stable residual masses (Rm -), and four were alive with disease. In all, 69 patients (26%) died owing to toxicity or uncontrolled germ cell malignancy, two patients due to second neoplasms (Table III) . Some 56% of deaths occurred during the first year from the date of commencement of chemotherapy, 82% during the first 2 years, and 85% during the first 3 years. Nine deaths (13%), eight caused by late relapse from germ cell tumour and one due to second malignancy, occurred more than 5 years from start of chemotherapy. All nine patients had received their primary chemotherapy according to the PVB protocol. The latest death from germ cell tumour was at 138 months. The overall 3 year survival was 77% [95% confidence interval (CI) 72 -82%], and 3 year progression-free survival was 71% (95% CI 65-77%).
Prognostic factors
Univariate analysis of prognostic variables is summarised in Table IV . The 5 year period of diagnosis reached borderline significance (P = 0.047, 2 d.f.). Comparing the period 1979 -83 with the period 1984-88, 3-year survival increased only modestly from 71% to 74%; the difference was not significant (P= 0.6). Patients treated during the period 1989-93 attained a 3-year survival of 87%, which was significantly better (P = 0.046) than the survival of patients treated in the period 1984-88.
Of the patient characteristics, tumour origin (testicular vs extragonadal) reached prognostic relevance. The following tumour markers (HCGO 10000 IU 1-1 and/or AFP ) 1000 ng ml-1), a mediastinal mass greater than 5 cm, the presence of liver, bone or brain metastases, and the presence of 20 or more lung metastases. In contrast, age at diagnosis was not a significant prognostic factor: patients over the age of 40 years had a 3-year survival of 69% compared with 78% for the younger patients (P = 0.3). Patients receiving etoposide-containing chemotherapy had a significantly improved survival compared with patients treated according to vinblastine-containing protocols (Table IV) .
All clinical variables achieving a significance level less than 0.05 on log-rank test were included in the multivariate analysis. Four pretreatment variables entered the model in the same order as in the second MRC study: the presence of liver, bone or brain metastases, high serum tumour marker levels, the presence of a mediastinal mass greater than 5 cm, and the presence of 20 or more lung metastases (Table V) . A total of 124 patients (47%) had at least one of these poor risk factors; the 3-year survival of this patient group was 61% (95% CI 53-70%) compared with 91% (95% CI 86-96%) for the patients with no poor risk factor (Figure 1) . Survival according to the number of poor risk features is shown in Figure 2 and worthwhile mentioning two cases of fatal cerebral infarction. The young age of the patients and a close temporal association to the administration of chemotherapy argued against coincidence. The incidence of major vascular events following chemotherapy of germ cell tumours has been reviewed elsewhere (Gerl, 1994) .
With our relatively large data set of patients with metastatic NSGCT treated at a single institution during the cisplatin era we could confirm the validity of the prognostic model which was suggested by the second MRC study (Mead et al., 1992) . It is of note that even the order of prognostic factors was identical. The presence of liver, bone or brain metastases was the most adverse feature, followed by high levels of serum tumour markers, a mediastinal mass greater than 5 cm, and by the presence of 20 or more lung metastases.
In contrast to the second MRC study and to another recent report (Aass et al., 1991), we could not confirm the prognostic relevance of age. Three year survival was slightly inferior in the older patients, but probably owing to the relatively small number of patients over 40 years, the difference did not reach statistical significance. A recent population-based study from Scotland also could not confirm the prognostic relevance of age (Hatton et al., 1995) . In contrast, we found that age was a prognostic factor in patients with recurrent or refractory germ cell tumours undergoing salvage treatment (Gerl et al., 1995b) .
Only 14% of the patients included in the second MRC study did not receive etoposide as a component of their treatment. This small proportion of patients was not found to carry an inferior prognosis compared with the remaining patients (Mead et al., 1992) . In contrast, we showed that etoposide-containing chemotherapy was an independent predictor of favourable long-term outcome. However, it is of note that good risk patients had an identical 3-year survival of 91% regardless of etoposide-or vinblastine- Therefore, the benefit of etoposide-containing chemotherapy outweighs the risk of secondary leukaemia in poor risk patients, whereas non-etoposide-containing protocols may be considered in good risk patients (Boshoff et al., 1995) . Overall, the risk of second cancer related to germ cell tumour therapy appears to be low. We observed only two cases of non-germ cell malignancies, and only in one of these cases a causative relationship between whole brain irradiation for cerebral relapse and the development of a glioblastoma almost 10 years later seemed probable. Five of our patients (2%) developed a second germ cell tumour on follow-up, underscoring that this risk is not eliminated by chemotherapy (Fossa and Aass, 1989) . Four of these patients presented with stage I disease and were treated by orchidectomy alone, while the fifth patient had stage H disease and underwent a second chemotherapy. All five patients are currently alive and disease-free.
It is of note that nine of 32 relapses from complete remission occurred after a disease-free interval of more than 2 years. A further five patients developed a late relapse from a second complete response or from a marker-negative response. Twelve of the 14 patients with late relapses had received PVB as primary chemotherapy. As in a recent report (Baniel et al., 1995) , long-term outcome of patients with late relapses was poor. Eight of the 14 patients ultimately died of their disease, and one is alive with uncontrolled malignancy. Although, in agreement with the second MRC study (Mead et al., 1992) , 85% of deaths due to germ cell tumour were observed within 3 years from commencement of chemotherapy, the occurrence of late relapses emphasises the need to report long-term results (Hitchins et al., 1989; Dearnaley et al., 1991) . Possibly the incidence of late relapses is lower in patients receiving etoposide-containing chemotherapy as suggested by a recent report (Dearnaley et al., 1991) , but our results do not allow for definite conclusions, since median follow-up in this subgroup is only 53 months. In contrast, patients receiving PVB have all passed through a follow-up period of 8 years in which the majority of late relapses may occur. In a recent report time to late relapse ranged from 2 to 32 years, with a median of 6.2 years (Baniel et al., 1995) .
It is of note that treatment results improved only modestly between 1984 and 1988 compared with the period 1979-83, as only 5% of poor risk patients received etoposide during 1979-83 compared with almost two-thirds in the following 5 year period. A more pronounced improvement in survival occurred between 1989 and 1993. Therefore, other factors than the inclusion of etoposide may be operative. Some reports suggested that it is the cumulative experience in pathology, surgery, radiology and biochemistry, in addition to that of the oncology staff, that leads to improved survival in specialist referral centres (Einhorn, 1986; Aass et al., 1991; Harding et al., 1993; Feuer et al., 1994; Howard et al., 1995) . A recent review suggested that centralised treatment may improve survival in cancer patients (Stiller, 1994) . Unfortunately, we are not able to compare our results with population-based data, as Germany does not have a national cancer registry at present. However, one report studying the mortality from testicular cancer between 1979 and 1989 described a more rapid decrease in Munich than in the rest of the Federal Republic (Hoelzel and Altwein, 1991) . Nevertheless, there is a trend of decentralisation of treatment of testicular cancer in Germany as shown by a slightly decreasing referral rate to our centre.
In conclusion, the analysis of our single institution data confirms the validity of the prognostic model that was suggested by the second MRC study. However, we could not find a prognostic significance of age. Cumulative experience, intensified therapy and the use of etoposide-containing chemotherapy regimens led to a marked improvement of long-term survival in patients with poor risk metastatic disease. The incidence of second non-germ cell malignancies is very low at present, but the observation time is too short to exclude an increase of solid tumours. The relatively high incidence of late relapses emphasises the need to report longterm results.
